MAPT and Brain atrophy: The hypothetical model of biomarkers in AD indicated that the presence of Aβ is related to the functioning of the vascular systems and growth.6,7 This model describes the integration of AD biomarkers, which may reflect an underlying pathophysiological sequence of the following events: (1) the presence of amyloid-β42 in the cerebrospinal fluid (CSF) is first detected (the same is true for tau blood biomarkers);8 (2) levels of tau protein in CSF are significantly increased; (3) hypometabolism of fluorodeoxyglucose occurs; (4) brain atrophy occurs; and (5) cognitive decline is noted.